A study by Dr. Raymond U. Osarogiagbon and colleagues found that such programs may benefit patients deemed too young or too old for lung cancer screening based on existing guidelines. Read more
At the end of 2023, the agency approved repotrectinib for ROS1+ NSCLC, granted priority review for tarlatamab for advanced SCLC, and asked for an additional confirmatory trial for sotorasib for KRAS G12C-mutated NSCLC. Read more
As the IASLC celebrates its 50th year, the association’s journal moves to online only and the American Cancer Society recommends expanding screening eligibility. Read more